Cretostimogene Grenadenorepvec is an oncolytic virus commercialized by Kissei Pharmaceutical, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to Globaldata, it is involved in 13 clinical trials, of which 3 were completed, 4 are ongoing, 4 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Cretostimogene Grenadenorepvec’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Cretostimogene Grenadenorepvec is expected to reach an annual total of $24 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Cretostimogene Grenadenorepvec Overview

CG-0070 is under development for the treatment of high grade non-muscle invasive bladder cancer (NMIBC), muscle invasive bladder cancer, metastatic bladder cancer, metastatic urothelial cancer and other solid tumors. The drug candidate is administered intravesically and intratumoral routes. CG-0070 is the first armed oncolytic virus therapy. It is engineered to secrete GM-CSF, an immune-stimulating hormone, which also serves as the adjuvant in GVAX cancer immunotherapy platform. It was under development for ovarian cancer, glioblastoma multiforme, lung cancer and head and neck cancer.

Kissei Pharmaceutical Overview

Kissei Pharmaceutical (Kissei) discovers, develops, manufactures, and sells pharmaceutical products. The company’s pharmaceutical products include urological medicine, metabolic endocrinology medicine, drugs for kidney and dialysis department, drugs for obstetrics and gynecology, ophthalmic medicine and rare disease medicine. It also develops and sells health foods including protein-controlled food, energy supply food, calorie-controlled food, and elderly-controlled food. Kissei conducts research to develop novel drugs and improve existing drugs and provide superior drugs to people worldwide. The company has sales offices across Japan and an overseas subsidiary in New Jersey, the US. Kissei is headquartered in Matsumoto, Japan.
The company reported revenues of (Yen) JPY67,493 million for the fiscal year ended March 2023 (FY2023), an increase of 3.2% over FY2022. The operating loss of the company was JPY1,063 million in FY2023, compared to an operating loss of JPY1,842 million in FY2022. In FY2023, the company recorded a net margin of 15.6%, compared to a net margin of 19.8% in FY2022. The company reported revenues of JPY20,881 million for the third quarter ended December 2023, an increase of 18.2% over the previous quarter.

For a complete picture of Cretostimogene Grenadenorepvec’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.